$1.49
2.61%
Nasdaq, Apr 21, 08:47 pm CET
ISIN
US34960Q1094
Symbol
FBIO
Sector
Industry

Fortress Biotech, Inc. Stock price

$1.53
-0.22 12.57% 1M
-0.28 15.47% 6M
-0.50 24.44% YTD
-0.24 13.56% 1Y
-14.07 90.19% 3Y
-31.92 95.43% 5Y
-63.57 97.65% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.03 2.00%
ISIN
US34960Q1094
Symbol
FBIO
Sector
Industry

Key metrics

Market capitalization $45.19m
Enterprise Value $39.51m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.68
P/S ratio (TTM) P/S ratio 0.78
P/B ratio (TTM) P/B ratio 1.88
Revenue growth (TTM) Revenue growth -31.76%
Revenue (TTM) Revenue $57.68m
EBIT (operating result TTM) EBIT $-111.15m
Free Cash Flow (TTM) Free Cash Flow $-131.19m
Cash position $57.26m
EPS (TTM) EPS $-2.99
P/E forward negative
P/S forward 0.62
EV/Sales forward 0.54
Short interest 15.60%
Show more

Is Fortress Biotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Fortress Biotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Fortress Biotech, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Fortress Biotech, Inc. forecast:

Buy
100%

Financial data from Fortress Biotech, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
58 58
32% 32%
100%
- Direct Costs 25 25
11% 11%
44%
32 32
42% 42%
56%
- Selling and Administrative Expenses 79 79
4% 4%
138%
- Research and Development Expense 57 57
46% 46%
99%
-104 -104
21% 21%
-180%
- Depreciation and Amortization 7.26 7.26
3% 3%
13%
EBIT (Operating Income) EBIT -111 -111
20% 20%
-193%
Net Profit -46 -46
24% 24%
-80%

In millions USD.

Don't miss a Thing! We will send you all news about Fortress Biotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fortress Biotech, Inc. Stock News

Neutral
GlobeNewsWire
20 days ago
SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the pr...
Neutral
GlobeNewsWire
21 days ago
Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; Checkpoint's lead product, UNLOXCYT™, approved by FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma FD...
Neutral
GlobeNewsWire
24 days ago
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma
More Fortress Biotech, Inc. News

Company Profile

Fortress Biotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel pharmaceutical and biotechnology products. It operates through the following segments: Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The company was founded on June 28, 2006 and is headquartered in New York, NY.

Head office United States
CEO Lindsay Rosenwald
Employees 101
Founded 2006
Website www.fortressbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today